The latest update is out from Wave Life Sciences ( (WVE) ).
Wave Life Sciences Ltd. has reported encouraging interim results from their Phase 2 FORWARD-53 clinical trial of WVE-N531, an investigational therapy for Duchenne muscular dystrophy amenable to exon 53 skipping, demonstrating substantial dystrophin expression and safety. The data suggests potential for monthly dosing and significant improvements in muscle health, with further details expected in early 2025. The company’s progress reflects a broader commitment to advancing RNA medicines, with additional clinical trials and an upcoming R&D Day to showcase their latest innovations.
See more insights into WVE stock on TipRanks’ Stock Analysis page.